Buzzetti E, Kalafateli M, Thorburn D, Davidson BR, Thiele M, Gluud LL, et al. Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011646. https://www.ncbi.nlm.nih.gov/pubmed/28368093
Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol-related liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2019. https://www.ncbi.nlm.nih.gov/pubmed/31314133
European Association for the Study of
the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018;69(1):154–81. https://www.ncbi.nlm.nih.gov/pubmed/29628280
Moreno C, Deltenre P, Senterre C, Louvet A, Gustot T, Bastens B, et al. Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids. Gastroenterology 2016;150(4):903-10 e8. https://www.ncbi.nlm.nih.gov/pubmed/26764182
Pavlov CS, Varganova DL, Casazza G, Tsochatzis E, Nikolova D, Gluud C. Glucocorticosteroids for people with alcoholic hepatitis. Cochrane Database Syst Rev 2019;4:CD001511. https://www.ncbi.nlm.nih.gov/pubmed/30964545
Saberi B, Dadabhai AS, Jang YY, Gurakar A, Mezey E. Current management of alcoholic hepatitis and future therapies. J Clin Transl Hepatol 2016;4(2):113–22. https://www.ncbi.nlm.nih.gov/pubmed/27350941
Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;372(17):1619–28. https://www.ncbi.nlm.nih.gov/pubmed/25901427
Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline for alcoholic hepatitis. Cochrane Database Syst Rev 2009;(4):CD007339. https://www.ncbi.nlm.nih.gov/pubmed/19821406
